Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies

NCT02189174 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
31
Enrollment
INDUSTRY
Sponsor class

Stopped Novartis decided to terminate the study considering safety and tolerability concerns and limited clinical activity with CLR457 study drug administered once daily (qd).

Conditions

Interventions

Sponsor

Novartis Pharmaceuticals